Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28812540 | 0.92 | KMT2A (0.70) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL16790448 | 0.89 | KMT2A (0.63) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL21525041 | 0.88 | KMT2A (0.61) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL793384 | 0.87 | KMT2A (0.85) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL28617673 | 0.87 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL163534 | 0.87 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL4741668 | 0.86 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29404046 | 0.86 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL30275540 | 0.86 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL1157227 | 0.85 | KMT2A (0.66) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| WO-2016202894-A1 | METHOD OF CONVERTING ALCOHOL TO HALIDE | UNIVERSITAET DES SAARLANDES (DE) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | KMT2A 4193/4885EPHX2 2557/4885FABP7 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.